April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Intravitreal Bevacizumab During Pregnancy
Author Affiliations & Notes
  • R. M. Tarantola
    Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
  • J. C. Folk
    Ophthalmology, Univ of Iowa Hospitals & Clinics, Iowa City, Iowa
  • H. C. Boldt, III
    Ophthalmology, Univ of Iowa Hosp & Clinics, Iowa City, Iowa
  • V. B. Mahajan
    Ophthalmology, University of Iowa, Iowa City, Iowa
  • Footnotes
    Commercial Relationships  R.M. Tarantola, None; J.C. Folk, None; H.C. Boldt, III, None; V.B. Mahajan, None.
  • Footnotes
    Support  Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2227. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. M. Tarantola, J. C. Folk, H. C. Boldt, III, V. B. Mahajan; Intravitreal Bevacizumab During Pregnancy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2227.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine if intraocular anti-VEGF agents are safe in pregnant women.

Methods: : This was a retrospective review of four women who received intravitreal bevacizumab while pregnant. Informed consent regarding the off-label use of the treatment and potential adverse effects was disclosed prior to treatment. Demographic data, ophthalmic findings, color photos, optical coherence tomography, number of injections, dose and drug used, history, and medical records after delivery were obtained from all subjects.

Results: : Four women were treated with intravitreal bevacizumab during five pregnancies. All patients had subfoveal choroidal neovascularization. The causes included presumed ocular histoplasmosis syndrome in two patients, punctuate inner choroidopathy in one patient, and sarcoid uveitis in one patient. Patients received a mean of 2.6 + 2.3 injections (range, 1-6 injections) of 1.25mg bevacizumab during pregnancy. Two patients were treated prior to pregnancy with thirteen and two injections respectively. One patient required two additional injections following pregnancy. The mean follow-up duration after the last injection was 12.5 + 3.7 months (range, 10-18 months). Snellen visual acuity improved in all four patients with a mean of 4.75 + 1.7 lines (range, 3-7 lines). At the most recent follow-up, all patients had involuted choroidal neovascularization that did not require additional treatment. There were no cases of endophthalmitis or other ocular complications related to injections. There were no cases of pregnancy complications. All patients had an uneventful pre-natal course and delivered healthy full-term infants.

Conclusions: : The risk of anti-VEGF in pregnancy is unknown and is currently the source of great debate and concern. These women probably would have developed irreversible vision loss had they not been treated while pregnant. Based on this series, it seems reasonable to offer pregnant patients the option of intravitreal bevacizumab.

Keywords: choroid: neovascularization • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.